Importance Unresected locally advanced non–small cell lung cancer (LA-NSCLC) shows
poor survival outcomes even after aggressive concurrent chemoradiotherapy. Whether …

Importance Non–small cell lung cancer (NSCLC) has relatively poor outcomes. Metformin
has significant data supporting its use as an antineoplastic agent. Objective To compare …

Background and purpose The aim was to investigate whether the use of metformin during
concurrent chemoradiotherapy (cCRT) for locally advanced non-small cell lung cancer …

Background In the absence of a targeted oncogenic driver mutation or high programmed
death‐ligand 1 expression, systemic therapy with platinum‐based doublet chemotherapy …

Importance Metformin hydrochloride is emerging as a repurposed anticancer drug.
Preclinical and retrospective studies have shown that it improves outcomes across a wide …

Purpose Our previous works demonstrated the ability of metformin to revert resistance to
gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in …

Rationale: Prior studies have shown an anticancer effect of metformin in patients with breast
and colorectal cancer. It is unclear, however, whether metformin has a mortality benefit in …

BACKGROUND: It has been reported that antidiabetic drugs affect the risk of cancer and the
prognosis of patients with diabetes, but few studies have demonstrated the influence of …

Diabetes mellitus (DM) is frequently increased in many countries and become a serious
health problem worldwide. Diabetes is associated with dysfunction of different organs such …

Background Acquired resistance has become the bottleneck affecting the efficacy of
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. Studies …